The latest column from Ted Slafsky, publisher and CEO of 340B Report, addresses the likeliest path forward for 340B federal legislation.
COLUMN: After 340B Hearing and New Bills Emerging; The Likely Path Forward
Despite its importance, the 340B drug discount program rarely ever goes under the Congressional spotlight. In fact, until the June [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.